Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI

Clinical Research in Cardiology

Volumn 100, Issue 10, 2011, Pages 907-914

  Behr, Tobias ^a   Kuch, Bernhard ^a   Behr, Werner ^a   Von Scheidt, Wolfgang ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

Clopidogrel; Platelets; Stent thrombosis; Stents; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PHENPROCOUMON; PRASUGREL; PROTON PUMP INHIBITOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANALYTIC METHOD; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ELECTRODE PLATELET AGGREGOMETRY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG MONITORING; DRUG RESISTANCE; DRUG SUBSTITUTION; ELECTRODES; FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TETRAZOLES; THIOPHENES; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054732930     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0321-4     Document Type: Article

References (42)

1. C Stettler S Wandel S Allemann, et al. 2007 Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis Lancet 370 937 948 17869634 10.1016/S0140-6736(07)61444-5 1:CAS:528:DC%2BD2sXhtVeqsL7E (Pubitemid 47393576)
2. S Cook S Windecker 2009 Early stent thrombosis: past, present, and future Circulation 119 657 659 19204315 10.1161/CIRCULATIONAHA.108.842757
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention (2006) ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention-summary article: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 47:216-235
4. DJ Angiolillo A Fernandez-Ortiz E Bernardo F Alfonso C Macaya TA Bass MA Costa 2007 Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 1505 1516 17418288 10.1016/j.jacc.2006.11.044 1:CAS:528:DC%2BD2sXjvFGgt7s%3D (Pubitemid 46517957)
5. JD Snoep MM Hovens JC Eikenboom, et al. 2007 Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am Heart J 154 221 231 17643570 10.1016/j.ahj.2007.04.014 1:CAS:528:DC%2BD2sXotVWrtrc%3D (Pubitemid 47069129)
6. D Sibbing S Braun T Morath, et al. 2009 Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 849 856 19264241 10.1016/j.jacc.2008.11.030 1:CAS:528:DC%2BD1MXlslagsrk%3D
7. P Buonamici R Marcucci A Migliorini, et al. 2007 Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2312 2317 17572245 10.1016/j.jacc.2007.01.094 1:CAS:528:DC%2BD2sXmsFKmu7o%3D (Pubitemid 46891710)
8. T Geisler H Langer M Wydymus, et al. 2006 Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2420 2425 17005534 10.1093/eurheartj/ehl275 1:CAS:528: DC%2BD28Xht1OksrzF (Pubitemid 44522148)
9. S Matetzky B Shenkman V Guetta, et al. 2004 Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 3171 3175 15184279 10.1161/01.CIR.0000130846.46168.03 1:CAS:528:DC%2BD2cXltVCgtro%3D
10. J Geiger L Teichmann R Grossmann B Aktas U Steigerwald U Walter R Schinzel 2005 Monitoring of clopidogrel action: comparison of methods Clin Chem 51 957 965 15817818 10.1373/clinchem.2004.047050 1:CAS:528:DC%2BD2MXkvF2nsr0%3D (Pubitemid 40740875)
11. O Toth A Calatzis S Penz H Losonczy W Siess 2006 Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood Thromb Haemost 96 781 788 17139373 1:CAS:528:DC%2BD2sXhslyiurk%3D (Pubitemid 44883819)
12. D Sibbing S Braun S Jawanski, et al. 2008 Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 121 126 18217143 1:CAS:528:DC%2BD1cXhtlWisr4%3D
13. M Klouche 2007 Diagnostic methods for platelet function analysis Transfus Med Hemother 34 20 32 10.1159/000098179 (Pubitemid 46177992)
14. T Behr W Behr W von Scheidt 2010 Monitoring of clopidogrel treatment by multiple electrode platelet aggregometry J Lab Med 34 99 107 1:CAS:528:DC%2BC3cXmvFWqtLo%3D
15. BK Lee SW Lee SW Park, et al. 2007 Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation Am J Cardiol 100 610 614 17697815 10.1016/j.amjcard.2007.03.070 1:CAS:528: DC%2BD2sXovFeksbg%3D (Pubitemid 47223135)
16. Wiviott SD, Antman EM, Gibson CM et al, TRITON-TIMI 38 Investigators (2006) Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152:627-635 (Pubitemid 44396884)
17. Cutlip DE, Windecker S, Mehran R et al, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344-2351 (Pubitemid 46685903)
18. M O'Donoghue SD Wiviott 2006 Clopidogrel response variability and future therapies. Clopidogrel: does one size fit all? Circulation 114 e600 e606 17130347 10.1161/CIRCULATIONAHA.106.643171 (Pubitemid 44847437)
19. L Bonello US Tantry R Marcucci, et al. 2010 Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 919 933 20828644 10.1016/j.jacc.2010. 04.047 1:CAS:528:DC%2BC3cXhtlWjt7jJ
20. M Cattaneo 2010 New P2Y(12) inhibitors Circulation 121 171 179 20048234 10.1161/CIRCULATIONAHA.109.853069
21. MJ Price 2009 Bedside evaluation of thienopyridine antiplatelet therapy Circulation 119 2625 2632 19451364 10.1161/CIRCULATIONAHA.107.696732
22. Price MJ, Berger PB, Teirstein PS et al, GRAVITAS Investigators (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097-1105
23. Althoff T, Fischer M, Langer E, Ziemer S, Baumann G (2009) Reduzierte Thrombozyten-inhibitorische Wirkung von Clopidogrel und ASS im Verlauf nach Stentimplantation bei akutem Myokardinfarkt gegenüber elektiver koronarer Stentimplantation. Clin Res Cardiol 98(Suppl 1), V1678. Abstract
24. T Cuisset C Frere J Quilici, et al. 2007 High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes Thromb Haemost 97 282 287 17264958 1:CAS:528:DC%2BD2sXkt1Cjs70%3D (Pubitemid 46592149)
25. R Marcucci R Paniccia E Antonucci, et al. 2007 Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy Thromb Haemost 98 844 851 17938810 1:CAS:528:DC%2BD2sXht12ju73O (Pubitemid 47555078)
26. M Gilard B Arnaud JC Cornily, et al. 2008 Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 256 260 18206732 10.1016/j.jacc.2007.06.064 1:CAS:528:DC%2BD1cXpt1Gksg%3D%3D
27. JM Siller-Matula AO Spiel IM Lang, et al. 2009 Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 148 19081411 10.1016/j.ahj.2009.03.015 (e1-e5)
28. DS Small NA Farid CD Payne, et al. 2008 Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 475 484 18303127 10.1177/0091270008315310 1:CAS:528:DC%2BD1cXkslKntLk%3D (Pubitemid 351389118)
29. PM Ho TM Maddox L Wang SD Fihn RL Jesse ED Peterson JS Rumsfeld 2009 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 937 944 19258584 10.1001/jama.2009.261 1:CAS:528:DC%2BD1MXivFejt7g%3D
30. DN Juurlink T Gomes DT Ko, et al. 2009 A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 713 718 19176635 10.1503/cmaj.082001
31. Stanek EJ (2009) http://www.theheart.org/article/977905.do. Accessed 3 Nov 2009
32. ML O'Donoghue E Braunwald EM Antman, et al. 2009 Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 989 997 19726078 10.1016/S0140-6736(09)61525-7
33. D Sibbing T Morath J Stegherr, et al. 2009 Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 714 719 19350116 1:CAS:528:DC%2BD1MXltVertbs%3D
34. JA Rassen NK Choudhry J Avorn S Schneeweiss 2009 Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2322 2329 19933932 10.1161/CIRCULATIONAHA.109.873497 1:CAS:528: DC%2BD1MXhsVOhtrfE
35. N von Beckerath A Kastrati A Wieczorek, et al. 2007 A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 1814 1819 10.1093/eurheartj/ehl489 (Pubitemid 47236637)
36. B Aleil G Rochoux JP Monassier JP Cazenave C Gachet 2007 Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases J Thromb Haemost 5 879 881 17403206 10.1111/j.1538-7836.2007.02338.x 1:STN:280:DC%2BD2s3gtV2ltQ%3D%3D (Pubitemid 46563597)
37. JW Ko Z Desta NV Soukhova T Tracy DA Flockhart 2000 In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6 Br J Clin Pharmacol 49 343 351 10759690 10.1046/j.1365-2125.2000.00175.x 1:CAS:528:DC%2BD3cXjtl2hsbc%3D (Pubitemid 30195277)
38. G Campo M Valgimigli D Gemmati, et al. 2007 Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study J Am Coll Cardiol 50 1132 1137 17868803 10.1016/j.jacc.2007.04.092 1:CAS:528:DC%2BD2sXhtVCmu7bO (Pubitemid 47375009)
39. H Neubauer S Lask A Engelhardt A Mügge 2008 How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification Thromb Haemost 99 357 362 18278186 1:CAS:528: DC%2BD1cXisFKmt78%3D (Pubitemid 351230967)
40. DJ Angiolillo SB Shoemaker B Desai, et al. 2007 Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study Circulation 115 708 716 17261652 10.1161/CIRCULATIONAHA.106.667741 1:CAS:528:DC%2BD2sXhtlGqtbg%3D (Pubitemid 46294761)
41. Mehta SR, Tanguay JF, Eikelboom JW et al, CURRENT-OASIS 7 trial investigators (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233-1243
42. Wiviott SD, Braunwald E, McCabe C et al, TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)